



Company Overview

Abeona Therapeutics is focused on developing and delivering gene therapy products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Epidermolysis Bullosa, Sanfilippo syndrome, Batten disease, and other rare disorders.

Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa

Nov 18 2021, 7:30 AM EST

Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference

Nov 17 2021, 7:30 AM EST

Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference

Nov 16 2021, 7:30 AM EST

Stock Overview

Symbol	ABEO
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week	\$ - \$

Investor Relations

ir@abeonatherapeutics.com

Management Team

Vishwas Seshadri, Ph.D., M.B.A.

Chief Executive Officer, Director

Edward Carr

Chief Financial Officer, Principal Financial Officer

Greg Gin

Vice President, Investor Relations and Corporate Communications

Brian Kevany, Ph.D.

Vice President, Chief Technical Officer

Kristina Maximenko

Vice President, Human Resources

Scott Nogi

Vice President, Business Operations

Brendan O'Malley, J.D., Ph.D.

Senior Vice President, General Counsel

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.